Sinopharm Holdings (01099.HK) received 1.377 million shares from J.P. Morgan Chase

Gelonghui, May 8 | According to the latest equity disclosure data from the Stock Exchange, on April 30, 2024, Sinopharm Holdings (01099.HK) obtained JPMorgan Chase & Co. increased its position by 1.37,000 shares at an average price of HK$20.0142 per share, involving approximately HK$26.559 million. After the increase in holdings, JPMorgan Chase & Co.'s latest number of positions was 81.0281 million shares, and the holding ratio increased from 5.93% to 6.03%.

Gelonghui Finance19:27 ET

Why We're Not Concerned About Sipai Health Technology Co., Ltd.'s (HKG:314) Share Price

It's not a stretch to say that Sipai Health Technology Co., Ltd.'s (HKG:314) price-to-sales (or "P/S") ratio of 1x right now seems quite "middle-of-the-road" for companies in the Consumer Retailing i

Simply Wall StMay 2 20:46 ET

Should You Think About Buying Sinopharm Group Co. Ltd. (HKG:1099) Now?

Sinopharm Group Co. Ltd. (HKG:1099), is not the largest company out there, but it saw a double-digit share price rise of over 10% in the past couple of months on the SEHK. Shareholders may appre

Simply Wall StMay 1 18:01 ET

Gene Technology Company Youxun Medical Presents Hong Kong Stock Exchange Shareholder Background Lineup Luxurious

Youxun Medical submitted an A1 prospectus to the Hong Kong Stock Exchange. The sole sponsor is CICC. The company is a platform-based genetic technology company engaged in the development and sale of clinical molecular testing instruments, products and services, including the three business segments of prenatal testing, precision oncology and pathogen testing. The company adopted the “LDT+IVD” dual-track business model and established a portfolio of products and services including 24 commercialized and 14 under development. The company proposed the competitive advantage of products and services in the market through the four core technologies of liquid biopsy, DNA methylation testing, NGS and POCT microfluidic biochips

Gelonghui FinanceApr 30 11:25 ET

Jinhuo Pharmaceutical Group (01110) awarded a total of 6.648 million bonus shares

Jinhuo Pharmaceutical Group (01110) issued an announcement on April 30, 2024, following the first award and the second time...

Zhitong FinanceApr 30 08:50 ET

Shanghai Pharmaceutical (601607.SH): New specifications for injectable parecoxib sodium have been approved

Gelonghui, April 30 | Shanghai Pharmaceutical (601607.SH) announced that its wholly-owned subsidiary Shangyao Dongying (Jiangsu) Pharmaceutical Co., Ltd., received the “Drug Supplement Application Approval Notice” issued by the State Drug Administration, and the new specification of the drug, 40 mg, was approved. Injectable parecoxib sodium is mainly used for short-term treatment of pain after surgery. It was first developed by Pfizer and marketed in Europe in 2002.

Gelonghui FinanceApr 30 06:36 ET